Laboratorio Farmaceutico Erfo 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Alessandro Cute

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	n/a
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	데이터 없음

최근 관리 업데이트

Recent updates

CEO

Alessandro Cute (54 yo)

no data

테뉴어

Dr. Alessandro Cute is President of the Board of Directors & Chief Executive Officer of Laboratorio Farmaceutico Erfo S.p.A. Dr. Cute joined at Laboratorio Farmaceutico Erfo S.p.A. in 2013.

Laboratorio Farmaceutico Erfo 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Less than half of directors are independent

Recent updates

Investor sentiment improves as stock rises 42%

First half 2024 earnings released: EPS: €0.034 (vs €0.049 in 1H 2023)

Less than half of directors are independent

New minor risk - Share price stability

Investor sentiment improves as stock rises 16%

New major risk - Revenue and earnings growth

New minor risk - Financial data availability

Investor sentiment improves as stock rises 19%

New major risk - Market cap size

Investor sentiment improves as stock rises 34%

New major risk - Market cap size

New major risk - Earnings quality

New minor risk - Share price stability

New major risk - Market cap size

Investor sentiment deteriorates as stock falls 18%

Laboratorio Farmaceutico Erfo S.p.A. (BIT:ERFO) completed the acquisition of 65% stake in Bodysano France on December 29, 2022.

Investor sentiment improved over the past week

Laboratorio Farmaceutico Erfo S.p.A. (BIT:ERFO) signed an agreement to acquire 65% stake in Bodysano France for €0.85 million.

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First half 2022 earnings released: EPS: €0 (vs €0 in 1H 2021)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

CEO

테뉴어